In 2024, Aurisco Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, Aurisco Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 2,731.19a | 2,014.95a | 1,137.61a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 57,520.25a | 48,964.95a | 48,022.32a | |
Total Scope 3 | 25,694.61a | 20,637.52a | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 13.5068a | 11.3425a | 7.8578a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Aurisco Pharmaceutical amounted to 60,251.44 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Aurisco Pharmaceutical increased by 18.19%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Aurisco Pharmaceutical were 2,731.19 metric tons of CO₂ equivalent (tCO₂e).a
Since 2022, Aurisco Pharmaceutical's Scope 1 emissions have increased by 140.08%, reflecting a rising long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Aurisco Pharmaceutical's Scope 1 emissions increased by 35.55%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Aurisco Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 57,520.25 tCO₂e without specifying the calculation method.a
Since 2022, Aurisco Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 19.78%, reflecting a rising long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2023), Aurisco Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) rose by 17.47% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2024, Aurisco Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Aurisco Pharmaceutical reported 25,694.61 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Aurisco Pharmaceutical includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Aurisco Pharmaceutical reported total Scope 3 emissions of 25,694.61 metric tons of CO₂ equivalent (tCO₂e).a
Compared to the previous year (2023), Aurisco Pharmaceutical's Scope 3 emissions increased by 24.5%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2024, Aurisco Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 2,731.19 tCO₂e and total revenues of USD 202 millions. This translates into an emissions intensity of 13.51 tCO₂e per millions USD.a
In 2024, Aurisco Pharmaceutical reported a Scope 1 emissions intensity of 13.51 tCO₂e per millions USD. Compared to the peer group median of 10.66, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Aurisco Pharmaceutical ranked 13 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Aurisco Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Aurisco Pharmaceutical reported a total carbon footprint of 85,946.05 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 20.01% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Aurisco Pharmaceutical's total carbon footprint was Scope 2 emissions, accounting for 66.93% of the company's total carbon footprint, followed by Scope 3 emissions at 29.9%.a